WO1995007103A1 - Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive - Google Patents

Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive Download PDF

Info

Publication number
WO1995007103A1
WO1995007103A1 PCT/US1994/009581 US9409581W WO9507103A1 WO 1995007103 A1 WO1995007103 A1 WO 1995007103A1 US 9409581 W US9409581 W US 9409581W WO 9507103 A1 WO9507103 A1 WO 9507103A1
Authority
WO
WIPO (PCT)
Prior art keywords
cold
amino acid
expectorant
propionic acid
antitussive
Prior art date
Application number
PCT/US1994/009581
Other languages
French (fr)
Inventor
Sekhar Mitra
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to EP94926020A priority Critical patent/EP0719156A1/en
Priority to BR9407414A priority patent/BR9407414A/en
Priority to JP7508695A priority patent/JPH09502201A/en
Priority to AU76040/94A priority patent/AU7604094A/en
Publication of WO1995007103A1 publication Critical patent/WO1995007103A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising certain amino acid salts of propionic acid non-steriodal anti-inflammatory agents along with at least one of (a) a decongestant, (b) an expectorant, (c) an 0 antihistamine, and (d) an antitussive.
  • the common cold although not usually a serious illness, is a highly pre ⁇ valent, discomforting and annoying infliction.
  • the term "common cold” is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. 5 While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling 0 acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.
  • Exemplary prior art formulations for treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith generally contain an analgesic (aspirin or acetaminophen) and one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.
  • non-steroidal anti-inflammatory drugs to combat inflammation and attendant pain is accepted medical practice.
  • the non-steroidals are commonly employed to relieve pain and inflammation associated with, for example, bursitis, arthritis, headache and the like.
  • drugs of the non-narcotic analgesic class of drugs are aspirin, acetaminophen, ibuprofen and naproxen.
  • Aspirin, acetaminophen and ibuprofen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- -symptom alleviating compositions.
  • compositions comprising certain amino acid salts of the propionic acid NSAIDs with at least one of (a) a decongestant, (b) an expectorant (c) and antihistamine, and (d) an antitussive provides improved treatment, management or mitigation of cold, cold-like and/or flu symptoms.
  • symptoms refer to coryza, nasal congestion, sinus congestion, sinus pain, upper respiratory infections, allergic rhinitis, otitis, sinitis, etc.
  • the present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising an amino acid salt of a propionic acid NSAID along with at least one of (a) a de ⁇ congestant, (b) an expectorant, (c) an antihistamine and (d) an antitussive.
  • the present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising an amino acid salt of a propionic acid NSAID along with at least one of (a) a de- congestant, (b) an expectorant (c) an antihistamine and (d) an antitussive.
  • amino acid salt refers to salts derived from pharmaceutically acceptable organic non-toxic bases of primary, secondary, tertiary and quaternary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, ornithine, arginine, histidine, caffeine, procaine, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purines, piperazine, piperidine, polyamine resins and the like.
  • the preferred non-steroidal anti-inflammatory agents useful in the com ⁇ position of the present invention include the amino acid salts of the propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic. Mixtures of these non-steroidal anti-inflammatory agents may also be employed. Of these propionic acid NSAIDs, ibuprofen, naproxen and ketoprofen are most preferred.
  • S(+) isomer of these NSAID salts.
  • S(+) as applied to the analgesic agents herein is intended to encompass the dextrorotatory or S(+) isomer of the amino acid salt derivatives thereof.
  • the expression "substantially free of the R(-) antipode” as used in conjunction with the term “S(+)” means that the S(+) enantiomer is sufficiently free it is R(-) antipode to exert the desired onset-hastened and enhanced analgesic effect. Practically speaking, this means that the active ingredient should contain at least 90% by weight of the S(+) enantiomer and 10% or less weight R(-) enantiomer.
  • the weight ratio of S(+) enantiomer to R(-) enantiomer is greater than 20:1, more preferably greater than 97:3. Most preferably the S(+) enantiomer is 99 or more % by weight free of R(-) enantiomer, i.e., the weight ratio of S to R is approximately equal to or greater than 99: 1.
  • the safe and effective amount of the amino acid salts of ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indo ⁇ profen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic generally ranges from about 7.5 mg to about lOOOmg, and are generally the same as their acid derivatives counterparts.
  • Useful dosage of these agents can be found in The Pbv. icians' Desk Reference, 47th Edition (1993) and in U.S. Patent 4,552,£99 to Sunshine et al., issued November 12, 1985, both of which are incorporated by reference herein.
  • the safe and effective amount of the amino acid salt of ibuprofen used in the compositions of the present invention generally ranges from about 50 to about 800 mg, preferably from about 50 to about 400 mg, more preferably from about 50 to about 200 mg and most preferably from about 50 to about 100 mg.
  • the safe and effective amount of the amino acid salt of flurbiprofen used in the compositions of the present invention generally ranges from about 12.5 to about 300 mg, preferably from about 12.5 to about 200 mg, more preferably from about 12.5 to about 100 mg and most preferably from about 12.5 to about 50 mg.
  • the safe and effective amount of the amino acid salt of ketoprofen used in the compositions of the present invention generally ranges from about 5 to about 100 mg, preferably from about 5 to about 75 mg, more preferably from about 5 to about 50 mg and most preferably from about 5 to about 25 mg.
  • the amount of the S(+) isomers of these agents will be about half of the amount of the racemic mixture.
  • compositions of the present invention also include at least one other pharmacological active selected from the following class: (a) a decongestant, (b) an expectorant (c) an antihistamine and (d) an antitussive.
  • a decongestant selected from the following class: (a) a decongestant, (b) an expectorant (c) an antihistamine and (d) an antitussive.
  • the decongestants useful in the compositions of the present invention include pseudoephedrine, phenyipro- panolamine, phenylephrine and ephedrine, their pharmaceutically acceptable salts, and mixtures thereof.
  • antitussives useful in the present invention include those such as dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, their pharmaceutically-acceptable salts, and mixtures thereof.
  • the antihistamines useful in the present invention include those such as chlorpheniramine, brompheniramine, dexchlo heniramine, dexbromphreniramine, triprolidine, azatadine, doxylamine, tripelennamine, cyproheptadine, hydroxyzine, clemastine, carbinoxamine, phenindamine, bromodiphenhydramine, pyrilamine, their pharmaceutically acceptable salts, as well as the non-sedating antihistamines which include acrivastine, AHR-11325, astemizole, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, warmthlastine, and terfenadine, their pharmaceutically acceptable salts and mixtures thereof.
  • the expectorants also known as mucolytic agents
  • the expectorants include glyceryl guaiacolate, terpin hydrate, ammonium chloride, N- -acetylcysteine and bromhexine, ambroxol, their pharmaceutically acceptable salts, and mixtures thereof. All of these components, as well as their acceptable dosage ranges are described in the following: U.S. Patent 4,783,465 to Sunshine et al., is ⁇ sued November 8, 1988, U.S. Patent 4,619,934 to Sunshine et al., issued October 28, 1986, which are incorporated by reference herein.
  • the pharmaceutical compositions of the present invention comprise the analgesic agent and other pharmacological active in a ratio of anal- gesic agent: pharmacological active of from about 200: 1 to about 1 : 1, preferably from about 50: 1 to about 1 : 1 and most preferably from about 10: 1 to about 1: 1.
  • oral dosage forms can be used, including such solid forms as tablets, capsules, granules, lozenges and bulk powders and liquid forms such as syrups and suspensions. These oral forms comprise a safe and effective amount, usually at least about 5% of the active component.
  • Solid oral dosage forms preferably contain from about 5% to about 95%, more preferably from about 10% to about 95%, and most preferably from about 25% to about 95% of the active component.
  • Liquid oral dosage forms preferably contain from about 1% to about 50% and more preferably from about 1% to about 25% and most preferably from about 3% to about 10% of the active component.
  • Tablets can be compressed, triturated, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow- -inducing agents. Also useful are soft gelatin capsules.
  • Liquid oral dosage forms include aqueous and nonaqueous solutions, emul ⁇ sions, pseudo emulsions, suspensions, and solutions and/or suspensions recons ⁇ tituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, taste-masking agents, coloring agents, and flavoring agents.
  • suitable solvents preservatives, emulsifying agents, suspending agents, diluents, sweeteners, taste-masking agents, coloring agents, and flavoring agents.
  • Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type.
  • the most preferred carrier is a suspension of the pharmaceutical composition in an aqueous vehicle containing a suitable suspending agent.
  • suitable suspending agents include Avicel RC-591 (a microcrystalline-cellulose/sodium carboxymethyl cellulose mixture available from FMC), guar gum and the like. Such suspending agents are well known to those skilled in the art.
  • the total water content based on the weight of the final composition, will generally range from about 20 to about 75%, and, preferably, from about 20 to about 40%, by weight/volume.
  • typical liquid formu- lations preferably contain a co-solvent, for example, propylene glycol, glycerin, sor- bitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients, such as flavoring oils and the like into the composition.
  • a co-solvent for example, propylene glycol, glycerin, sor- bitol solution and the like
  • the compositions of this invention preferably contain from about 5 to about 25 volume/volume percent and, most preferably, from about 10 to about 20 volume/ volume percent, of the co-solvent.
  • compositions of this invention may optionally contain one or more other known therapeutic agents, particularly those commonly utilized in cough/cold preparations, such as, for example, a s bronchodilator such as terbutaline, aminophylline, epinephrine, isoprenaline, metaproterenol, bitoteroL, theophylline and albuterol as well as other analgesic agents such as acetaminophen and aspirin.
  • a s bronchodilator such as terbutaline, aminophylline, epinephrine, isoprenaline, metaproterenol, bitoteroL, theophylline and albuterol
  • analgesic agents such as acetaminophen and aspirin.
  • a highly preferred optional component is caffeine.
  • ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final product, antioxidants, for example, butylated hydroxy anisole or butylated hydroxy toluene, and preservatives, for example, methyl or propyl paraben or sodium benzoate, to prolong and enhance shelf life.
  • natural or artificial sweeteners for example, butylated hydroxy anisole or butylated hydroxy toluene
  • preservatives for example, methyl or propyl paraben or sodium benzoate
  • the amount of the pharmaceutical composition administered depends upon the percent of active ingredients within its formula, which is a function of the amount of the naphthalene derivative and any optional components such as a decongestant, cough suppressant, expectorant and/or antihistamine required per dose, stability, release characteristics and other pharmaceutical parameters.
  • each individual dosage of the pharma ⁇ ceutical compositions of the present invention range from about 1 mg/kg to about 25 mg kg, preferably from about 2 mg/kg to about 15 mg kg and most preferably from about 3 mg/kg to about 10 mg/kg.
  • a hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:
  • Triturate active ingredients and q.s. with lactose to selected capsule size.
  • Administration of 1 or 2 of the above capsules to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
  • a hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:
  • Triturate active ingredients and q.s. with lactose to selected capsule size are administered to selected capsule size.
  • Administration of 1 or 2 of the above capsules to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
  • a liquid composition for oral administration is prepared by combining the following ingredients:
  • the purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer.
  • the sodium citrate, citric acid, and actives other than ibuprofen are added sequentially and dissolved with agitation.
  • the glycerin and liquid sugar are then colorants added.
  • the colorants are added to purified water (approximately 0.5% of the final batch volume).
  • This colorant solution is then added to the first batch container.
  • the ketoprofen lysinate is added to the alcohol while stirring.
  • the propylene glycol, other actives and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container.
  • the remaining purified water is added to the resulting mixture and stirred.
  • Administration of 10 ml to 20 ml (2 to 4 teaspoonsful) to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
  • a liquid composition for oral administration is prepared by combining the following ingredients:
  • the purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin 1 mixer.
  • the sodium citrate, citric acid, pseudoephedrine HC1 and chlorpheniramine maleate are added sequentially and dissolved with agitation.
  • the glycerin and liquid sugar are then added.
  • the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch con ⁇ tainer.
  • the ibuprofen argininate is added to the alcohol while stirring.
  • the propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container.
  • the remaining purified water is added to the resulting mixture and stirred.
  • a liquid composition for oral administration is prepared by combining the following ingredients:
  • the purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer.
  • the sodium citrate, citric acid, pseudoephedrine HC1 and chlorpheniramine maleate are added sequentially and dissolved with agitation.
  • the glycerin and liquid sugar are then added.
  • the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container.
  • the S (+) ibuprofen lysinate and dextro ⁇ methorphan HBr are added sequentially to the alcohol while stirring.
  • the propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container.
  • the remaining purified water is added to the resulting mixture and stirred.

Abstract

The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising certain amino acid salts of propionic acid non-steriodal anti-inflammatory agents along with at least one of (a) a decongestant, (b) an expectorant, (c) an antihistamine and (d) an antitussive.

Description

COMPOSITIONS CONTAINING AN AMINO ACID SALT OF PROPIONIC ACID NON-STEROIDAL ANTIINFLAMMATORY AGENT AND AT LEAST ONE OF A DECONGESTANT, AN EXPECTORANT,
AN ANTIHISTAMINE AND AN ANTITUSSIVE
TECHNICAL FIELD 5 The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising certain amino acid salts of propionic acid non-steriodal anti-inflammatory agents along with at least one of (a) a decongestant, (b) an expectorant, (c) an 0 antihistamine, and (d) an antitussive.
BACKGROUND OF THE INVENTION The common cold, although not usually a serious illness, is a highly pre¬ valent, discomforting and annoying infliction. The term "common cold" is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. 5 While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling 0 acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.
Early symptoms may be minimal with only mild malaise, sore throat and nasal complaints. With rhinovirus infection, symptoms of nasal discharge, nasal congestion, and sneezing usually commence on the first day of illness and progress 25 to maximum severity by the second or third day. Along with nasal symptoms may come sore, dry or scratchy throat and hoarseness and cough. Other symptoms may include mild burning of the eyes, loss of smell and taste, a feeling of pressure or fullness in the sinuses or ears, headache, and vocal impairment. Fever can occur, but is uncommon. Influenza infection generally includes fever, often of sudden 30 onset and persisting for several days, and with great severity; generalized aches and pains; fatigue and weakness; and chest discomfort.
At present, only symptomatic treatment is available for the common cold. The costs of treating colds with over-the-counter medications in the United States is estimated at an annual cost of over 1.5 billion dollars. The direct costs of treatment 35 in outpatient clinics is estimated at almost four billion dollars. Indirect costs, based on the amount of loss in wages because of restricted activity are substantially higher. Exemplary prior art formulations for treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith generally contain an analgesic (aspirin or acetaminophen) and one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants. The use of non-steroidal anti-inflammatory drugs to combat inflammation and attendant pain is accepted medical practice. The non-steroidals are commonly employed to relieve pain and inflammation associated with, for example, bursitis, arthritis, headache and the like. Among the most commonly used drugs of the non-narcotic analgesic class of drugs are aspirin, acetaminophen, ibuprofen and naproxen. Aspirin, acetaminophen and ibuprofen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- -symptom alleviating compositions. These commercially marketed products generally contain in addition to aspirin, acetaminophen or ibuprofen, one or more antihistaminics, decongestants, cough-suppressants, antitussives and expectorants. The ornithine, lysine and arginine salts of ibuprofen useful for providing relief from pain and inflammation have been disclosed in, for example, U.S. 4,279,926 to Bruzzese et al., issued July 21, 1981. A process for the preparation of ibuprofen lysine tablets has been disclosed in EP 505,180, published March 19, 1992. The use of the S(+) form of ibuprofen has been disclosed in, for example, U.S. Patent 4,851,444 to Sunshine et al. issued July 25, 1989 and in combination with antihistamines in WO 9,205,783 to Gates et al. published April 16, 1992.
The use of naproxen as well as other of the newer non-steroidal anti-inflam¬ matory agents (i.e., excluding aspirin, acetaminophen and phenacetin) in the preparation of cough/cold pharmaceutical compositions has been disclosed in, for example, U.S. Patent 4,552,899 to Sunshine et al. issued November 12, 1985. The use of some of these newer NSAID's alone to treat upper respiratory infections has been disclosed in "Therapeutic Utility of Naproxen in Acute Upper Respiratory Infection - Multiclinical Double Blind Study" Kansenshogaku Zasshi 52 (5): 148- -163 (1978), "Clinical Evaluation of Sulindac (Clinoril®) in the Treatment of Acute Upper Respiratory Tract Inflammation - Double Blind Comparison With Ibuprofen", Kansenshogaku Zasshi. Vol. 57, No. 3, pp. 260-272 (1983); "Double Blind Controlled Study of Miroprofen in Acute Upper Respiratory Tract Infections. Comparison with Ibuprofen" Kansenshogaku Zasshi. Vol. 50, No. 5, pp. 435-453, 1982, "Therapeutic Effects of Fenbufen on the Common Cold. Multiclinic Double- -Blind Study" Kansenshogaku Zasshi. Vol. 51, No. 4, pp. 184-196, (1977); "Clinical Evaluation of Clinoril Tablets in Acute Respiratory Tract Infections", Kansenshogaku Zasshi. Vol. 56, No. 12, pp. 1186-1195, 1982. The present inventors have found that selected compositions comprising certain amino acid salts of the propionic acid NSAIDs with at least one of (a) a decongestant, (b) an expectorant (c) and antihistamine, and (d) an antitussive provides improved treatment, management or mitigation of cold, cold-like and/or flu symptoms.
It is therefore an object of the present invention to provide a method for the treatment of cough, cold, cold-like and/or flu symptoms in a mammalian organism in need of such treatment comprising administering to such organism the compositions of the present invention. Such symptoms as used herein refer to coryza, nasal congestion, sinus congestion, sinus pain, upper respiratory infections, allergic rhinitis, otitis, sinitis, etc.
SUMMARY OF THE INVENTION The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising an amino acid salt of a propionic acid NSAID along with at least one of (a) a de¬ congestant, (b) an expectorant, (c) an antihistamine and (d) an antitussive.
All percentages and ratios used herein are by weight unless otherwise in¬ dicated. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising an amino acid salt of a propionic acid NSAID along with at least one of (a) a de- congestant, (b) an expectorant (c) an antihistamine and (d) an antitussive.
The term "amino acid salt" refers to salts derived from pharmaceutically acceptable organic non-toxic bases of primary, secondary, tertiary and quaternary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, ornithine, arginine, histidine, caffeine, procaine, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purines, piperazine, piperidine, polyamine resins and the like.
The propionic acid derivatives of the non-steroidal anti-inflammatory agents which are useful in the compositions of the present invention are well-known to those skilled in the art and are disclosed in, for example, U.S. Patent 4,552,899 to
Sunshine et al., issued November 12, 1985, incorporated by reference herein. For detailed disclosure of the chemical structure, synthesis, side effects, etc., of non-steroidal anti-inflammatory agents, reference may be had to standard texts, including Anti-inflammatory and Anti-Rheumatic Drugs. K. D. Rainsford, Vol. I-EH, CRC Press, Boca Raton, (1985), and Anti-inflammatory Agents. Chemistry and Pharmacology. 1, R. A. Scherrer, et al., Academic Press, New York (1 74), both of which are incorporated by reference herein.
The preferred non-steroidal anti-inflammatory agents useful in the com¬ position of the present invention include the amino acid salts of the propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic. Mixtures of these non-steroidal anti-inflammatory agents may also be employed. Of these propionic acid NSAIDs, ibuprofen, naproxen and ketoprofen are most preferred.
Most preferred for use herein is the S(+) isomer of these NSAID salts. The term "S(+)" as applied to the analgesic agents herein is intended to encompass the dextrorotatory or S(+) isomer of the amino acid salt derivatives thereof. The expression "substantially free of the R(-) antipode" as used in conjunction with the term "S(+)" means that the S(+) enantiomer is sufficiently free it is R(-) antipode to exert the desired onset-hastened and enhanced analgesic effect. Practically speaking, this means that the active ingredient should contain at least 90% by weight of the S(+) enantiomer and 10% or less weight R(-) enantiomer. Preferably, the weight ratio of S(+) enantiomer to R(-) enantiomer is greater than 20:1, more preferably greater than 97:3. Most preferably the S(+) enantiomer is 99 or more % by weight free of R(-) enantiomer, i.e., the weight ratio of S to R is approximately equal to or greater than 99: 1.
The safe and effective amount of the amino acid salts of ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indo¬ profen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic generally ranges from about 7.5 mg to about lOOOmg, and are generally the same as their acid derivatives counterparts. Useful dosage of these agents can be found in The Pbv. icians' Desk Reference, 47th Edition (1993) and in U.S. Patent 4,552,£99 to Sunshine et al., issued November 12, 1985, both of which are incorporated by reference herein.
For example, the safe and effective amount of the amino acid salt of ibuprofen used in the compositions of the present invention generally ranges from about 50 to about 800 mg, preferably from about 50 to about 400 mg, more preferably from about 50 to about 200 mg and most preferably from about 50 to about 100 mg. The safe and effective amount of the amino acid salt of flurbiprofen used in the compositions of the present invention generally ranges from about 12.5 to about 300 mg, preferably from about 12.5 to about 200 mg, more preferably from about 12.5 to about 100 mg and most preferably from about 12.5 to about 50 mg. The safe and effective amount of the amino acid salt of ketoprofen used in the compositions of the present invention generally ranges from about 5 to about 100 mg, preferably from about 5 to about 75 mg, more preferably from about 5 to about 50 mg and most preferably from about 5 to about 25 mg. Generally, the amount of the S(+) isomers of these agents will be about half of the amount of the racemic mixture.
The compositions of the present invention also include at least one other pharmacological active selected from the following class: (a) a decongestant, (b) an expectorant (c) an antihistamine and (d) an antitussive. The decongestants useful in the compositions of the present invention include pseudoephedrine, phenyipro- panolamine, phenylephrine and ephedrine, their pharmaceutically acceptable salts, and mixtures thereof. The antitussives useful in the present invention include those such as dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, their pharmaceutically-acceptable salts, and mixtures thereof. The antihistamines useful in the present invention include those such as chlorpheniramine, brompheniramine, dexchlo heniramine, dexbromphreniramine, triprolidine, azatadine, doxylamine, tripelennamine, cyproheptadine, hydroxyzine, clemastine, carbinoxamine, phenindamine, bromodiphenhydramine, pyrilamine, their pharmaceutically acceptable salts, as well as the non-sedating antihistamines which include acrivastine, AHR-11325, astemizole, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, their pharmaceutically acceptable salts and mixtures thereof. The expectorants (also known as mucolytic agents) useful in the present invention include glyceryl guaiacolate, terpin hydrate, ammonium chloride, N- -acetylcysteine and bromhexine, ambroxol, their pharmaceutically acceptable salts, and mixtures thereof. All of these components, as well as their acceptable dosage ranges are described in the following: U.S. Patent 4,783,465 to Sunshine et al., is¬ sued November 8, 1988, U.S. Patent 4,619,934 to Sunshine et al., issued October 28, 1986, which are incorporated by reference herein. Preferably, the pharmaceutical compositions of the present invention comprise the analgesic agent and other pharmacological active in a ratio of anal- gesic agent: pharmacological active of from about 200: 1 to about 1 : 1, preferably from about 50: 1 to about 1 : 1 and most preferably from about 10: 1 to about 1: 1.
Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules, lozenges and bulk powders and liquid forms such as syrups and suspensions. These oral forms comprise a safe and effective amount, usually at least about 5% of the active component. Solid oral dosage forms preferably contain from about 5% to about 95%, more preferably from about 10% to about 95%, and most preferably from about 25% to about 95% of the active component. Liquid oral dosage forms preferably contain from about 1% to about 50% and more preferably from about 1% to about 25% and most preferably from about 3% to about 10% of the active component.
Tablets can be compressed, triturated, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow- -inducing agents. Also useful are soft gelatin capsules.
Liquid oral dosage forms include aqueous and nonaqueous solutions, emul¬ sions, pseudo emulsions, suspensions, and solutions and/or suspensions recons¬ tituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, taste-masking agents, coloring agents, and flavoring agents. Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms, are described in U.S. Patent 3,903,297, Robert, issued September 2, 1975, incorporated by reference herein. Techniques and compositions for making solid oral dosage forms are described in Marshall, "Solid Oral Dosage Forms," Modern Pharmaceutics. Vol. 7. (Banker and Rhodes, editors), 359-427 (1979), incorporated by reference herein. Techniques and compositions for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are described in Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (1980), incorporated herein by reference. In preparing the liquid oral dosage forms, the active component is incor¬ porated into an aqueous-based orally acceptable pharmaceutical carrier consistent with conventional pharmaceutical practices. An "aqueous-based orally acceptable pharmaceutical carrier" is one wherein the entire or predominant solvent content is water. Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type. The most preferred carrier is a suspension of the pharmaceutical composition in an aqueous vehicle containing a suitable suspending agent. Suitable suspending agents include Avicel RC-591 (a microcrystalline-cellulose/sodium carboxymethyl cellulose mixture available from FMC), guar gum and the like. Such suspending agents are well known to those skilled in the art. While the amount of water in the compositions of this invention can vary over quite a wide range depending upon the total weight and volume of the active component and other optional non-active ingredients, the total water content, based on the weight of the final composition, will generally range from about 20 to about 75%, and, preferably, from about 20 to about 40%, by weight/volume.
Although water itself may make up the entire carrier, typical liquid formu- lations preferably contain a co-solvent, for example, propylene glycol, glycerin, sor- bitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients, such as flavoring oils and the like into the composition. In general, therefore, the compositions of this invention preferably contain from about 5 to about 25 volume/volume percent and, most preferably, from about 10 to about 20 volume/ volume percent, of the co-solvent.
The compositions of this invention may optionally contain one or more other known therapeutic agents, particularly those commonly utilized in cough/cold preparations, such as, for example, a s bronchodilator such as terbutaline, aminophylline, epinephrine, isoprenaline, metaproterenol, bitoteroL, theophylline and albuterol as well as other analgesic agents such as acetaminophen and aspirin. A highly preferred optional component is caffeine. Other optional ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final product, antioxidants, for example, butylated hydroxy anisole or butylated hydroxy toluene, and preservatives, for example, methyl or propyl paraben or sodium benzoate, to prolong and enhance shelf life.
METHOD OF TREATMENT The amount of the pharmaceutical composition administered depends upon the percent of active ingredients within its formula, which is a function of the amount of the naphthalene derivative and any optional components such as a decongestant, cough suppressant, expectorant and/or antihistamine required per dose, stability, release characteristics and other pharmaceutical parameters.
Usually from about 1 mg kg to about 50 mg/kg per day, preferably from about 2 mg kg to about 30 mg/kg per day and most preferably from about 3 mg kg per day to about 20 mg/kg per day of the pharmaceutical composition is administered as described herein. This amount can be given in a single dose, or, preferably, in multiple (two to six) doses repeatedly or sustained release dosages over the course of treatment. Generally, each individual dosage of the pharma¬ ceutical compositions of the present invention range from about 1 mg/kg to about 25 mg kg, preferably from about 2 mg/kg to about 15 mg kg and most preferably from about 3 mg/kg to about 10 mg/kg. While dosages higher than the foregoing are effective to provide relief from cough, cold-like, flu and flu-like symptoms, care must be taken, as with any drug, in some individuals to prevent adverse side effects. The following examples illustrate embodiments of the subject invention wherein both essential and optional ingredients are combined. EXAMPLE I
A hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:
Ingredient Amount
Ibuprofen Lysinate 200 mg Pseudoephedrine HC1 30 mg
Triturate active ingredients and q.s. with lactose to selected capsule size. Administration of 1 or 2 of the above capsules to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
EXAMPLE π A hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:
Ingredient Amount
Naproxen Lysinate 200 mg
Pseudoephedrine HC1 30 mg Astemizole 5 mg
Glyceiyl guaiacolate 100 mg
Triturate active ingredients and q.s. with lactose to selected capsule size. Administration of 1 or 2 of the above capsules to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms. EXAMPLE m
A liquid composition for oral administration is prepared by combining the following ingredients:
Ingredient % W7V
Ketoprofen Lysinate 1.00
Alcohol (95%) 25.000
Pseudoephedrine HC1 0.30 Propylene Glycol 25.000
Sodium Citrate 2.000
Citric Acid 0.250
Liquid Sugar (Simple Syrup) 25.000
Glycerin 7.000
Colorants 0.008
Flavor 0.500
Water, Purified QS 100.000
The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, and actives other than ibuprofen are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then colorants added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container. In a separate container the ketoprofen lysinate is added to the alcohol while stirring. The propylene glycol, other actives and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred. Administration of 10 ml to 20 ml (2 to 4 teaspoonsful) to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
EXAMPLE IV A liquid composition for oral administration is prepared by combining the following ingredients:
Ingredient % W/V
Ibuprofen Argininate 1.00
Chlorpheniramine Maleate 0.02
Pseudoephedrine HC1 0.30
Alcohol (95%) 25.00
Propylene Glycol 25.00
Sodium Citrate 2.00
Citric Acid 0.25
Liquid Sugar (Simple Syrup) 25.00
Glycerin 7.00
Colorants 0.008
Flavor 0.50
Water, Purified QS 100.00 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin1 mixer. The sodium citrate, citric acid, pseudoephedrine HC1 and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch con¬ tainer. In a separate container the ibuprofen argininate is added to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
Administration of 10 ml to 20 ml (2 to 4 Teaspoonsful) to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE V A liquid composition for oral administration is prepared by combining the following ingredients:
Ingredient % W/V
S(+) Ibuprofen Lysinate 1.00
Pseudoephedrine HC1 0.30
Chlorpheniramine Maleate 0.02
Dextromethorphan HBr 0.15
Alcohol (95%) 25.00
Propylene Glycol 25.00
Sodium Citrate 2.00
Citric Acid 0.25
Liquid Sugar (Simple Syrup) 25.00
Glycerin 7.00
Colorants 0.008
Flavor 0.50
Water, Purified QS 100.00 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, pseudoephedrine HC1 and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a separate container the colorants are added to purified water (approximately 0.5% of the final batch volume). This colorant solution is then added to the first batch container. In a separate container the S (+) ibuprofen lysinate and dextro¬ methorphan HBr are added sequentially to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
Administration of 10 ml to 20 ml (2 to 4 teaspoonful) to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
SϋβSTlTUTE SHEET (RULE 26)

Claims

What is Claimed is:
1. A composition for providing improved treatment, management or miti¬ gation of cold, cold-like and/or flu symptoms by administering a safe and effective amount of a composition comprising an amino acid salt of a propionic acid nonsteroidal anti-inflammatory agent along with at least one of (a) a decongestant, (b) an expectorant, (c) an antitussive and (d) an antitussive.
2. A pharmaceutical composition according to Claim 1 wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofen, preferably wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, flurbiprofen, and ketoprofen and wherein said amino acid salt is selected from the group consisting of triethylamine, tripropylamine, 2-dimethylaminoethanol. 2-diethylaminoethanol, lysine, ornithine, arginine, histidine, caffeine, procaine, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purine, piperazine and piperidine and mixtures thereof.
3. A pharmaceutical composition according to any of the preceding Claims wherein: said decongestant is pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, mixtures thereof or pharmaceutically acceptable salts thereof; wherein said antitussive is selected from the group consisting of dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, mixtures thereof or pharmaceutically acceptable salts thereof; wherein said expectorant is an expectorant or mucolytic such as glyceiyl guaiacolate, terpin hydrate, ammonium chlo¬ ride, N-acetylcysteine, bromhexine and ambroxol, mixtures thereof or pharmaceutically acceptable salts thereof; and wherein said antihis¬ tamine is selected from the group consisting of chlorpheniramine, brom¬ pheniramine, dexchloφheniramine, dexbromphreniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bro- modiphenhydramine, pyrilamine, acrivastine, AHR- 1 1325, phenindamine, astemizole, azatadine, azelastine, cetirizine, ebastine, ke¬ totifen, lodoxamide, loratidine, levocabastine, mequitazine. oxatomide, setastine, tazifylline, temelastine, and terfenadine, mixtures thereof or pharmaceutically acceptable salts thereof.
4. A pharmaceutical composition according to any of the preceding Claims which comprises the S(+) enantiomer of the amino acid salt of a propionic acid nonsteroidal anti-inflammatory agent.
5. A pharmaceutical composition according to any of the preceding Claims comprising from 5 to 50 mg S(+)-ketoprofen lysinate.
6. A pharmaceutical composition according to any of Claims 1 through 4 comprising from 50 to 800 mg S(+)-ibuprofen lysinate.
7. A pharmaceutical composition according to any of Claims 1 through 4 comprising from 50 to 800 mg S(+)-naproxen lysinate.
8. A method for the treatment of cough, cold, cold-like and/or flu symptoms in a mammalian organism in need of such treatment comprising administering to such organism the composition of any of the preceding Claims.
PCT/US1994/009581 1993-09-07 1994-08-24 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive WO1995007103A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP94926020A EP0719156A1 (en) 1993-09-07 1994-08-24 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
BR9407414A BR9407414A (en) 1993-09-07 1994-08-24 Compositions containing a non-steroidal propionic acid anti-inflammatory agent amino acid salt and at least one decongestant an expectorant an antihistamine and an antitussive
JP7508695A JPH09502201A (en) 1993-09-07 1994-08-24 Composition containing amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of decongestant, expectorant, antihistamine and antitussive agent
AU76040/94A AU7604094A (en) 1993-09-07 1994-08-24 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11692793A 1993-09-07 1993-09-07
US08/116,927 1993-09-07

Publications (1)

Publication Number Publication Date
WO1995007103A1 true WO1995007103A1 (en) 1995-03-16

Family

ID=22370083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009581 WO1995007103A1 (en) 1993-09-07 1994-08-24 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Country Status (7)

Country Link
EP (1) EP0719156A1 (en)
JP (1) JPH09502201A (en)
CN (1) CN1130354A (en)
AU (1) AU7604094A (en)
BR (1) BR9407414A (en)
CA (1) CA2170488A1 (en)
WO (1) WO1995007103A1 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
GB2311940A (en) * 1996-04-08 1997-10-15 Ucb Sa Pharmaceutical compositions for the treatment of rhinitis
WO1997044022A1 (en) * 1996-05-20 1997-11-27 G.D. Searle & Co. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
WO1998042322A2 (en) * 1997-03-26 1998-10-01 Korbonits Dezso Antitussive compositions
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
WO1999015173A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
WO2000012071A2 (en) * 1998-08-29 2000-03-09 Miklos Ghyczy Pharmaceutical and/or diet product
WO2000030715A1 (en) * 1998-11-25 2000-06-02 Chinoin Gyógyszer És Vegyészeti Composition containing an analgesic and a xanthine or a xanthine derivative
EP1107740A1 (en) * 1998-08-25 2001-06-20 Chris E. Platt Timed release tablet comprising naproxen and pseudoephedrine
US6291527B1 (en) 1998-04-11 2001-09-18 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
WO2001074341A2 (en) * 2000-03-30 2001-10-11 Schering Corporation Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
WO2001089527A2 (en) * 2000-05-24 2001-11-29 Schering Corporation Pharmaceutical composition comprising loratadine and a nasal decongestant
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
EP1283043A1 (en) * 2000-05-17 2003-02-12 Senju Pharmaceutical Co., Ltd. Ophthalmic solution
WO2003020258A1 (en) * 2001-09-04 2003-03-13 Boehringer Ingelheim International Gmbh Anti-influenza drugs
ES2189682A1 (en) * 2001-12-11 2003-07-01 Esteve Labor Dr Drinkable preparation comprising ketoprofen and use thereof in the simultaneous treatment of a group of animals of respiratory diseases
EP1405646A2 (en) * 2002-10-02 2004-04-07 Yung Shin Pharm. Ind. Co. Ltd. Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same
WO2004058236A1 (en) * 2002-12-20 2004-07-15 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
WO2005007146A1 (en) * 2003-07-16 2005-01-27 Boehringer Ingelheim International Gmbh Ambroxol for treating chronic nociceptive pains
EP1572206A2 (en) * 2002-12-18 2005-09-14 Wyeth Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
WO2006021166A1 (en) * 2004-08-21 2006-03-02 Romulus Balaban Procaine combination therapy
US7122539B2 (en) 1998-07-28 2006-10-17 Nicox S.A. Nitric esters and nitrate salts of specific drugs
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
EP1720537A2 (en) * 2004-02-17 2006-11-15 Wyeth Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
EP1755561A2 (en) * 2004-06-02 2007-02-28 Wyeth Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
EA008765B1 (en) * 2004-11-22 2007-08-31 Закрытое Акционерное Общество «Научно-Производственное Объединение "Антивирал"» (Зао «Нпо "Антивирал"») Antiinflammatory preparation
WO2008002514A2 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
ES2338972A1 (en) * 2008-10-01 2010-05-13 Farmalider, S.A. Liquid pharmaceutical composition of ibuprophene and codeine for its oral administration, its procedure of preparation and utilization of the same (Machine-translation by Google Translate, not legally binding)
ES2350670A1 (en) * 2009-06-10 2011-01-26 Polichem, S.L. Veterinary composition of ketoprophene (Machine-translation by Google Translate, not legally binding)
WO2011058374A1 (en) * 2009-11-13 2011-05-19 Biocopea Limited Drug combination with theobromine and its use in therapy
WO2011107617A1 (en) * 2010-03-01 2011-09-09 Farmalider, S.A. Liquid ibuprofen/codeine pharmaceutical composition for oral administration, the method for preparation thereof and use thereof
EP2525789A1 (en) * 2010-01-19 2012-11-28 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US8703158B2 (en) 2009-06-16 2014-04-22 Biocopea Limited Theobromine for the treatment of cough
US8846083B2 (en) * 2004-02-03 2014-09-30 Philippe Perovitch Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method
US8957095B2 (en) 2009-10-26 2015-02-17 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
RU2564904C2 (en) * 2009-12-14 2015-10-10 ИнФерст Хэлткэр Лимитед Theobromine-decongestant combination and application thereof for treating cough
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10576041B2 (en) 2016-09-26 2020-03-03 The Procter & Gamble Company Extended relief dosage form
WO2022119431A1 (en) * 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
JP4549618B2 (en) * 2001-11-22 2010-09-22 第一三共ヘルスケア株式会社 Composition for rhinitis
JP4695326B2 (en) * 2001-12-21 2011-06-08 第一三共ヘルスケア株式会社 Pharmaceutical composition for rhinitis
JP4614638B2 (en) * 2002-06-07 2011-01-19 第一三共株式会社 Analgesic composition
JP4614640B2 (en) * 2002-07-04 2011-01-19 第一三共株式会社 Antipyretic composition
WO2005123052A1 (en) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Drug composition containing ambroxol and erdosteine or acetylcysteine
CN1323662C (en) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof
JP2009007332A (en) * 2007-05-25 2009-01-15 Daiichi Sankyo Healthcare Co Ltd Pharmaceutical composition containing azelastines and ephedorines
CN101544572B (en) * 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 Ambroxol derivative and method for preparing same
CN103446587A (en) * 2011-12-28 2013-12-18 汪明 Application of mastocyte inhibitor in preparation of medicine for resisting influenza virus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017171A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-decongestant combinations
WO1992017177A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-antitussive combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017171A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-decongestant combinations
WO1992017177A1 (en) * 1991-04-01 1992-10-15 Merck & Co., Inc. Ibuprofen-antitussive combinations

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
GB2311940A (en) * 1996-04-08 1997-10-15 Ucb Sa Pharmaceutical compositions for the treatment of rhinitis
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US6489329B2 (en) 1996-04-08 2002-12-03 Ucb S.A. Pharmaceutical compositions for the treatment of rhinitis
GB2311940B (en) * 1996-04-08 2000-07-19 Ucb Sa Pharmaceutical compositions for the treatment of rhinitis
US6030643A (en) * 1996-05-20 2000-02-29 G.D. Searle & Co. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
WO1997044022A1 (en) * 1996-05-20 1997-11-27 G.D. Searle & Co. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
US6171618B1 (en) 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6537573B2 (en) 1996-05-29 2003-03-25 Pfizer Inc Combination dosage form comprising cetirizine and pseudoephedrine
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
US6107281A (en) * 1997-01-13 2000-08-22 Nutri-Quest, Inc. Compounds and their combinations for the treatment of influenza infection
WO1998042322A3 (en) * 1997-03-26 1998-12-17 Dezso Korbonits Antitussive compositions
US6348470B1 (en) 1997-03-26 2002-02-19 Korbonits Dezsoe Antitussive compositions
WO1998042322A2 (en) * 1997-03-26 1998-10-01 Korbonits Dezso Antitussive compositions
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
WO1999015173A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
US6291527B1 (en) 1998-04-11 2001-09-18 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
US7122539B2 (en) 1998-07-28 2006-10-17 Nicox S.A. Nitric esters and nitrate salts of specific drugs
EP1107740A1 (en) * 1998-08-25 2001-06-20 Chris E. Platt Timed release tablet comprising naproxen and pseudoephedrine
EP1107740A4 (en) * 1998-08-25 2002-03-06 Platt Chris Timed release tablet comprising naproxen and pseudoephedrine
WO2000012071A3 (en) * 1998-08-29 2000-06-15 Miklos Ghyczy Pharmaceutical and/or diet product
WO2000012071A2 (en) * 1998-08-29 2000-03-09 Miklos Ghyczy Pharmaceutical and/or diet product
WO2000030715A1 (en) * 1998-11-25 2000-06-02 Chinoin Gyógyszer És Vegyészeti Composition containing an analgesic and a xanthine or a xanthine derivative
WO2001074341A2 (en) * 2000-03-30 2001-10-11 Schering Corporation Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
WO2001074341A3 (en) * 2000-03-30 2002-05-16 Schering Corp Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
EP1283043A1 (en) * 2000-05-17 2003-02-12 Senju Pharmaceutical Co., Ltd. Ophthalmic solution
EP1283043A4 (en) * 2000-05-17 2003-07-02 Senju Pharma Co Ophthalmic solution
KR100776577B1 (en) 2000-05-17 2007-11-16 센주 세이야꾸 가부시키가이샤 Ophthalmic solution
WO2001089527A2 (en) * 2000-05-24 2001-11-29 Schering Corporation Pharmaceutical composition comprising loratadine and a nasal decongestant
WO2001089527A3 (en) * 2000-05-25 2003-10-16 Schering Corp Pharmaceutical composition comprising loratadine and a nasal decongestant
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
WO2003020258A1 (en) * 2001-09-04 2003-03-13 Boehringer Ingelheim International Gmbh Anti-influenza drugs
EP1437134A1 (en) * 2001-09-04 2004-07-14 Boehringer Ingelheim International GmbH Anti-influenza drugs
EP1437134A4 (en) * 2001-09-04 2009-03-11 Boehringer Ingelheim Int Anti-influenza drugs
AU2002361264B2 (en) * 2001-12-11 2007-07-26 Ecuphar N.V. Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain
ES2189682A1 (en) * 2001-12-11 2003-07-01 Esteve Labor Dr Drinkable preparation comprising ketoprofen and use thereof in the simultaneous treatment of a group of animals of respiratory diseases
WO2003053430A1 (en) * 2001-12-11 2003-07-03 Laboratorios Del Dr. Esteve, S.A. Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain
EP1405646A3 (en) * 2002-10-02 2004-04-21 Yung Shin Pharm. Ind. Co. Ltd. Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same
EP1405646A2 (en) * 2002-10-02 2004-04-07 Yung Shin Pharm. Ind. Co. Ltd. Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same
EP1572206A2 (en) * 2002-12-18 2005-09-14 Wyeth Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US7863287B2 (en) 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
AU2003301188B2 (en) * 2002-12-18 2009-07-02 Pf Consumer Healthcare 1 Llc Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
EP1572206A4 (en) * 2002-12-18 2007-07-18 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US6979689B2 (en) 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
WO2004058236A1 (en) * 2002-12-20 2004-07-15 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
WO2005007146A1 (en) * 2003-07-16 2005-01-27 Boehringer Ingelheim International Gmbh Ambroxol for treating chronic nociceptive pains
US8846083B2 (en) * 2004-02-03 2014-09-30 Philippe Perovitch Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method
EP1720537A2 (en) * 2004-02-17 2006-11-15 Wyeth Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
EP1720537A4 (en) * 2004-02-17 2007-10-03 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
EP1755561A2 (en) * 2004-06-02 2007-02-28 Wyeth Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
EP1755561B1 (en) * 2004-06-02 2016-11-23 Wyeth LLC Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
WO2006021166A1 (en) * 2004-08-21 2006-03-02 Romulus Balaban Procaine combination therapy
EA008765B1 (en) * 2004-11-22 2007-08-31 Закрытое Акционерное Общество «Научно-Производственное Объединение "Антивирал"» (Зао «Нпо "Антивирал"») Antiinflammatory preparation
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
WO2006119844A2 (en) * 2005-05-11 2006-11-16 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
WO2006119844A3 (en) * 2005-05-11 2007-04-12 Jordanian Pharmaceutical Mfg Controlled release oral drug delivery system
WO2008002514A2 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
WO2008002514A3 (en) * 2006-06-26 2008-10-16 Brian M Levine Combination cough treatment compounds and method of treating common coughs
ES2338972A1 (en) * 2008-10-01 2010-05-13 Farmalider, S.A. Liquid pharmaceutical composition of ibuprophene and codeine for its oral administration, its procedure of preparation and utilization of the same (Machine-translation by Google Translate, not legally binding)
ES2350670A1 (en) * 2009-06-10 2011-01-26 Polichem, S.L. Veterinary composition of ketoprophene (Machine-translation by Google Translate, not legally binding)
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9675618B2 (en) 2009-06-16 2017-06-13 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US8703158B2 (en) 2009-06-16 2014-04-22 Biocopea Limited Theobromine for the treatment of cough
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9700561B2 (en) 2009-06-16 2017-07-11 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10751331B2 (en) 2009-10-26 2020-08-25 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
US8957095B2 (en) 2009-10-26 2015-02-17 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
US9895360B2 (en) 2009-10-26 2018-02-20 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
WO2011058374A1 (en) * 2009-11-13 2011-05-19 Biocopea Limited Drug combination with theobromine and its use in therapy
RU2564904C2 (en) * 2009-12-14 2015-10-10 ИнФерст Хэлткэр Лимитед Theobromine-decongestant combination and application thereof for treating cough
US10463637B2 (en) 2010-01-19 2019-11-05 Catalent Ontario Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US9480667B2 (en) 2010-01-19 2016-11-01 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2525789A1 (en) * 2010-01-19 2012-11-28 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2525789A4 (en) * 2010-01-19 2014-04-30 Accucaps Ind Ltd Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP3909567A1 (en) * 2010-01-19 2021-11-17 Catalent Ontario Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US11896566B2 (en) 2010-01-19 2024-02-13 Catalent Ontario Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
GB2490840B (en) * 2010-03-01 2017-06-07 Farmalider Sa Liquid ibuprofen/codeine pharmaceutical composition for oral administration, the method for preparation thereof and use thereof
WO2011107617A1 (en) * 2010-03-01 2011-09-09 Farmalider, S.A. Liquid ibuprofen/codeine pharmaceutical composition for oral administration, the method for preparation thereof and use thereof
GB2490840A (en) * 2010-03-01 2012-11-14 Farmalider Sa Liquid ibuprofen/codeine pharmaceutical composition for oral administration, the method for preparation thereof and use thereof
US10576041B2 (en) 2016-09-26 2020-03-03 The Procter & Gamble Company Extended relief dosage form
US11433030B2 (en) 2016-09-26 2022-09-06 The Procter & Gamble Company Extended relief dosage form
WO2022119431A1 (en) * 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases

Also Published As

Publication number Publication date
JPH09502201A (en) 1997-03-04
AU7604094A (en) 1995-03-27
CA2170488A1 (en) 1995-03-16
BR9407414A (en) 1996-11-12
CN1130354A (en) 1996-09-04
EP0719156A1 (en) 1996-07-03

Similar Documents

Publication Publication Date Title
WO1995007103A1 (en) Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US5648358A (en) Compositions and methods for treating respiratory disorders
CA2146637C (en) Pharmaceutical compositions and methods for treating cold symptoms
AU8744398A (en) Compositions and methods for treating respiratory disorders
CA2170485C (en) Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
WO1994014476A1 (en) Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
WO1997004808A1 (en) Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
IE913184A1 (en) Method for treating respiratory disorders
AU672279B2 (en) Compositions containing caffeine and S(+)-ibuprofen or S(+)-flurbiprofen or S(+)-ketoprofen
JP2017132819A (en) Pharmaceutical composition containing loxoprofen or salt thereof
AU8915891A (en) Dextromethorphan antitussive compositions
CA2090234C (en) Method for providing improved analgesic effect

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193312.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP PL RU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2170488

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994926020

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994926020

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994926020

Country of ref document: EP